Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

3.53
Delayed Data
As of Sep 19
 +0.12 / +3.52%
Today’s Change
3.20
Today|||52-Week Range
10.04
-3.81%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$109.9M

Company Description

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Contact Information

Corvus Pharmaceuticals, Inc.
863 Mitten Road
Burlingame California 94010
P:(650) 900-4520
Investor Relations:
(650) 900-4522

Employees

Shareholders

Individual stakeholders66.11%
Other institutional45.00%
Mutual fund holders13.64%

Top Executives

Richard A. MillerChairman, President & Chief Executive Officer
Leiv LeaCFO & Principal Accounting Officer
Mehrdad MobasherChief Medical Officer & Vice President
Daniel W. HuntChief Business Officer & Senior Vice President
Joseph J. BuggyExecutive Vice President-Discovery Research